The Anti CD47 Drugs Market encompasses innovative therapies designed to block the CD47 “don’t eat me” signal on cancer cells, thereby enabling macrophages and other immune effectors to selectively engulf and destroy malignant cells. Key product offerings include humanized monoclonal antibodies, bispecific antibodies, fusion proteins, and novel antibody fragments that exhibit high affinity for CD47. These biologics demonstrate advantages such as targeted tumor cell clearance, reduced off-target toxicity, enhanced compatibility with existing chemotherapies, and improved patient safety profiles. Anti CD47 Drugs Market immuno-oncology gains traction, anti-CD47 agents address unmet needs in hematologic malignancies and solid tumors resistant to checkpoint inhibitors. The development of next-generation constructs also opens new market opportunities for combination regimens, personalized medicine approaches, and companion diagnostics. Ongoing clinical trials are fueling market insights that drive strategic collaborations, shaping favorable market dynamics and fueling market growth. The seamless integration of anti-CD47 therapies into treatment algorithms underscores rising market demand and robust market forecasts.

The anti CD47 drugs market is estimated to be valued at USD 0.20 Bn in 2025 and is expected to reach USD 2.46 Bn by 2032, growing at a compound annual growth rate (CAGR) of 43.1% from 2025 to 2032.

Key Takeaways
Key players operating in the Anti CD47 Drugs Market are

·         Bristol Myers Squibb,

·         ALX Oncology,

·         Trillium Therapeutics,

·         Innovent Biologics,

·         Forty Seven.

These market companies are aggressively advancing clinical pipelines, securing licensing agreements, and forging strategic partnerships to bolster product portfolios. Bristol Myers Squibb leverages its global commercialization expertise and expansive R&D infrastructure to optimize anti-CD47 antibody candidates in combination with other immunotherapies. ALX Oncology focuses on next-generation biologics and bispecific constructs that aim to differentiate in terms of safety and efficacy. Trillium Therapeutics, now part of larger market research initiatives, has generated critical market insights through Phase II data that reinforce its competitive positioning. Innovent Biologics and Forty Seven continue to drive market share gains through targeted collaborations, trial expansions in Asia Pacific, and industry-leading market analysis that identifies emerging segments and unmet needs.

Get More Insight On: Anti CD47 Drugs Market

Get this Report in Japanese Language: 抗CD47薬市場

Get this Report in Korean Language: 항CD47약물시장